ARS Pharmaceuticals
SPRY
187 hedge funds and large institutions have $1.48B invested in ARS Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 82 increasing their positions, 47 reducing their positions, and 22 closing their positions.
175% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $4.05M
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
74% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 47
54% more capital invested
Capital invested by funds: $960M → $1.48B (+$516M)
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
8.32% more ownership
Funds ownership: 77.73% → 86.06% (+8.3%)
2% more funds holding
Funds holding: 184 → 187 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$24.9M |
| 2 |
SCA
Southpoint Capital Advisors
New York
|
+$24.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.8M |
| 5 |
Goldman Sachs
New York
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
-$12.6M |
| 2 |
DM
Deerfield Management
New York
|
-$11.4M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.21M |
| 4 |
RA
Royce & Associates
New York
|
-$5.58M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$5.15M |
SPRY Hedge Fund Activity: Q2 2025 in Review
187 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2025, worth a combined $1.48B — up 54% from $960M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SPRY positions and 22 closed out — a net gain of 5 holders — while 82 added to existing stakes and 47 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $24.9M. The largest seller was Levin Capital Strategies, cutting an estimated $12.6M.
- 187 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2025, up from 184 in Q1 2025.
- Funds reported $1.48B of ARS Pharmaceuticals stock for Q2 2025, up 54% quarter-over-quarter.
- 27 funds opened new ARS Pharmaceuticals positions in Q2 2025 and 22 closed out, a net change of +5 holders.
- The largest ARS Pharmaceuticals buyer in Q2 2025 was Adage Capital Partners, an estimated $24.9M added.
- The largest ARS Pharmaceuticals seller in Q2 2025 was Levin Capital Strategies, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2025.